Effect of beta-glucan on immune response in lung cancer patients
Official title: Beta-glucan's Immuno-modulatory Effect on Non-Small Cell Lung Cancer
Run by University of Louisville · NCT00682032 · Data updated 2026-11-12
This study tests if a dietary supplement called beta-glucan can help boost the immune system in people with non-small cell lung cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University of Louisville Academic / other |
| Locations | 1 site (Louisville, Kentucky) |
| Status | Recruiting |
| Started | October 2008 |
| Main results expected | April 2025 |
| Study ends | March 2029 |
| Registry record updated | January 10, 2025 |
| Trial ID | NCT00682032 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with a confirmed diagnosis of non-small cell lung cancer who have not received treatment within the last six months.
✕Probably not a fit
Patients currently undergoing immunosuppressive therapy or with uncontrolled intercurrent illnesses may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the impact of beta-glucan, a dietary supplement derived from baker's yeast, on the immune system of patients diagnosed with non-small cell lung cancer (NSCLC). The research aims to determine whether beta-glucan can enhance the body's ability to fight cancer by stimulating white blood cells. Participants will include treatment-naive individuals with a confirmed diagnosis of NSCLC, and the study will assess the safety and efficacy of beta-glucan in this context.
Why it matters
Potential benefit: If successful, this study could provide a new, non-invasive treatment option that enhances immune response in lung cancer patients.
How similar studies have gone: Previous studies have shown promising results with beta-glucan in animal models, but this approach in humans is still being explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
AIM 2: Inclusion Criteria: * suspected or definitive diagnosis of non-small cell lung cancer (NSCLC) * treatment naive or no treatment within 6 months prior to enrollment * able to swallow pills * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 * absolute neutrophil count (ANC) at least 1500/microl * able to understand and willing to sign a written informed consent document Exclusion Criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements AIM 3: Inclusion Criteria: * resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon * treatment naive * able to swallow pills * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * must be an operative candidate * absolute neutrophil count (ANC) at least 1500/microl * able to understand and willing to sign a written informed consent document Exclusion Criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Where it's running
-
James Graham Brown Cancer Center
Louisville, Kentucky, United States Recruiting
Study contacts
- Principal investigator: Goetz H Kloecker, MD — James Graham Brown Cancer Center
- Study coordinator: Clinical Trials Office, Brown Cancer Center
- Email: ctobcc@louisville.edu
- Phone: (502) 562-3429
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.